Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Metabasis Therapeutics (MBRX) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (5)	6/27/2005 5:33:36 PM
From: Ian@SI	Respond to of 66

09:26 ET Metabasis Therapeutics and Merck announce collaboration (MBRX) 3.19 :Metabasis Therapeutics (MBRX) and Merck & Co (MRK) announced today that they have formed a collaboration to research, develop and commercialize novel small molecule therapeutics with potential to treat several diseases, including type II diabetes, hyperlipidemia and obesity, by activation of an enzyme in the liver called AMP-activated Protein Kinase (AMPK). Under the terms of the agreement, both Metabasis and Merck will conduct discovery efforts and contribute drug candidates to the collaboration. MRK will make a payment of $5 mln on signature of the agreement and will provide MBRX with funding for its research contribution to the program. In the event that a product is developed and marketed for use in patients for a single indication, the total cash payments to MBRX, excluding royalties, would be approximately $54 mln. If a product is approved for additional indications MRK would make additional milestone payments, which could bring the total cash payments to MBRX to $74 mln.